Punit Marathe

发表

Anticipating and Minimizing Drug Interactions in a Drug Discovery and Development Setting: An Industrial Perspective

A. D. Rodrigues, Sean Kim, Ragini Vuppugalla, 2010 .

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Malcolm Rowland, Thierry Lavé, Volker Fischer, 2011, Journal of pharmaceutical sciences.

Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.

Punit Marathe, Ravindra Tejwani, Arvind Mathur, 2008, Bioorganic & medicinal chemistry letters.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.

Punit Marathe, John S Tokarski, Toomas Mitt, 2002, Journal of medicinal chemistry.

5-((4-Aminopiperidin-1-yl)methyl)pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.

Henry Wong, Punit Marathe, John S Tokarski, 2007, Bioorganic & medicinal chemistry letters.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets.

Thierry Lavé, Rhys D O Jones, James W T Yates, 2011, Journal of pharmaceutical sciences.

N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent.

Punit Marathe, John S Tokarski, J. Tokarski, 2004, Journal of medicinal chemistry.

Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.

Henry Wong, Punit Marathe, John S Tokarski, 2007, Bioorganic & medicinal chemistry letters.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

Industry Perspective on Contemporary Protein-Binding Methodologies: Considerations for Regulatory Drug-Drug Interaction and Related Guidelines on Highly Bound Drugs.

Stacy Ho, Li Di, Avijit Ghosh, 2017, Journal of pharmaceutical sciences.

New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.

Henry Wong, Punit Marathe, John S Tokarski, 2007, Bioorganic & medicinal chemistry letters.

Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys

Jinping Gan, Michael D. Reily, Hong Shen, 2018, Drug Metabolism and Disposition.